Storys zum Thema Krankheit

ARTCLINE GmbH

ARTCLINE successfully completes capital increases of EUR 4.4 million

Rostock, Germany (ots) - Today ARTCLINE GmbH announced the successful completion of two further capital increases. In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8 million. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6 ...

Norgine

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with ...

STADA Arzneimittel AG

Press release: STADA continues with double-digit sales and profit growth in 2023

FDX Fluid Dynamix GmbH

4

FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX

RHEACELL GmbH und Co. KG

Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘

Helmholtz Munich

Rising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target

Leipzig Tourismus und Marketing GmbH

5

Pioneering Heart Surgery and Medical Congresses in Leipzig

Helmholtz Munich

Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial

Helmholtz Munich

What Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications

Acousia Therapeutics GmbH

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...

Sysmex Europe SE

Strengthening the Direct Sales and Service System for Business Expansion in Italy

Biomay AG

Biomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy

STADA Arzneimittel AG

Press release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara

STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...

Acousia Therapeutics GmbH

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...

Helmholtz Munich

Cells of the Future: A Key To Reprogramming Cell Identities

Helmholtz Munich

New Source of Stem Cells in Injury-Affected Brains of Patients

LTS Lohmann Therapie-Systeme AG

LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches

Takeda Pharma Vertrieb GmbH & Co. KG

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)

Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...

Grünenthal Group

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...

Grünenthal Group

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...

Fruit Vegetables Europe

Ten benefits of a daily intake of citrus fruits during winter season

Helmholtz Munich

Understanding the Role of GIP in Managing Diabetes and Obesity

The increasing amount of patients with obesity and type 2 diabetes benefit greatly from the recently developed GIPR:GLP-1R co-agonists. These novel compounds lead to substantial weight loss, offering a revolutionary approach to patients worldwide. Although the hormone glucose-dependent insulinotropic polypeptide (GIP) was already shown by Helmholtz Munich scientists to decrease body weight via the brain GIP receptor, the ...

ARTTIC Innovation GmbH

2

PIONEER+ becomes Big Data Platform for Prostate Cancer of the EAU's UroEvidenceHub

Fruit Vegetables Europe

The easiest fruit celebrates its 'Apple Day'